Companies

Marksans Pharma gets 8 observations from USFDA for its Goa facility

PTI New Delhi | Updated on March 07, 2019 Published on March 07, 2019

Representative image   -  istock.com/JK1991

The site will continue to supply all approved ANDAs to the US markets

Marksans Pharma on Thursday said it has received eight observations from the United States Food and Drug Administration (USFDA) after the inspection of its Goa facility.

“The inspection of the facility took place between February 25 to March 6, 2019 resulting in a Form 483 with eight observations,” it added.

None of these observations are considered either critical or repetitive in nature, the company said.

However, it did not provide any details about the observations.

“The company is highly confident of closing these expeditiously and remains committed to global standards of quality and compliance,” it said.

The site will continue to supply all approved abbreviated new drug applications (ANDAs) to the US markets. The inspection will help the company receive approval for pending ANDAs, Marksans Pharma said.

As per the USFDA, a FDA Form 483 is issued to a firm’s management at the conclusion of an inspection “when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.”

Shares of Marksans Pharma closed at Rs 26.15 per scrip on BSE, down 2.43 per cent from its previous close.

Published on March 07, 2019
This article is closed for comments.
Please Email the Editor